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Tadalaﬁl Enhances Immune Signatures in Response to
Neoadjuvant Nivolumab in Resectable Head and Neck
Squamous Cell Carcinoma
Adam J. Luginbuhl1, Jennifer M. Johnson2, Larry A. Harshyne3, Alban J. Linnenbach4, Sanket K. Shukla4,
Angela Alnemri1, Gaurav Kumar3, David M. Cognetti1, Joseph M. Curry1, Nikita Kotlov5, Zoya Antysheva5,
Sandrine Degryse5, Kyle Mannion6, Michael K. Gibson7, James Netterville6, Brandee Brown6,
Rita Axelrod2, Ralph Zinner2, Madalina Tuluc8, Stacey Gargano8, Benjamin E. Leiby9, Ayako Shimada9,
My G. Mahoney4, Ubaldo Martinez-Outschoorn2, Ulrich Rodeck4,†, Young J. Kim6, Andrew P. South4, and
Athanassios Argiris2

Purpose: We hypothesize that the addition of the phosphodiesterase-5 inhibitor tadalaﬁl to the PD-1 inhibitor nivolumab,
is safe and will augment immune-mediated antitumor responses
in previously untreated squamous cell carcinoma of the head and
neck (HNSCC).
Patients and Methods: We conducted a two-arm multiinstitutional neoadjuvant randomized trial in any-stage resectable
HNSCC (NCT03238365). Patients were stratiﬁed at randomization
by human papillomavirus (HPV) status. Patients in both arms
received nivolumab 240 mg intravenously on days 1 and 15
followed by surgery on day 28. Those in the combination therapy
arm also received tadalaﬁl 10 mg orally once daily for 4 weeks.
Imaging, blood, and tumor were obtained pretreatment and posttreatment for correlative analysis.
Results: Neoadjuvant therapy was well-tolerated with no grade 3
to 5 adverse events and no surgical delays. Twenty-ﬁve of 46 (54%)

Introduction
Immunotherapy with immune checkpoint inhibitors (ICIs) has
been incorporated in the standard-of-care management of recurrent
or metastatic squamous cell carcinoma of the head and neck (HNSCC),
and it is now being evaluated as promising treatment in less advanced
disease. Two ICIs, the anti–PD-1 mAbs pembrolizumab and nivolumab, have shown safety and improved overall survival in patients
with platinum-refractory recurrent or metastatic HNSCC as compared
1
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Note: Supplementary data for this article are available at Clinical Cancer
Research Online (http://clincancerres.aacrjournals.org/).

evaluable patients had a pathologic treatment response of ≥20%,
including three (7%) patients with a complete pathologic response.
Regardless of HPV status, tumor proliferation rate was a negative
predictor of response. A strong pretreatment T-cell signature in the
HPV-negative cohort was a predictor of response. Tadalaﬁl
altered the immune microenvironment, as evidenced by transcriptome data identifying enriched B- and natural killer cell
gene sets in the tumor and augmented effector T cells in the
periphery.
Conclusions: Preoperative nivolumab  tadalaﬁl is safe in
HNSCC and results in more than 50% of the patients having a
pathologic treatment response of at least 20% after 4 weeks of
treatment. Pretreatment specimens identiﬁed HPV statusdependent signatures that predicted response to immunotherapy
while posttreatment specimens showed augmentation of the
immune microenvironment with the addition of tadalaﬁl.

with investigator’s choice standard therapies (1, 2). A subsequent
phase III trial (KEYNOTE-048) demonstrated pembrolizumab plus
platinum and 5-ﬂuorouracil is an appropriate ﬁrst-line treatment for
recurrent or metastatic HNSCC, and pembrolizumab monotherapy is
an appropriate ﬁrst-line treatment for patients with PD-L1–positive
recurrent or metastatic HNSCC (3). These results have solidiﬁed the
role of immunotherapy in recurrent or metastatic HNSCC and
prompted further clinical investigations, including the use of combination immunotherapies to enhance response rates. Previously, PD-1
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Translational Relevance

inhibitors were used in the neoadjuvant therapy setting in untreated
patients with advanced human papillomavirus (HPV)–negative
(HPV) tumors with promising results (4–6).
Despite encouraging results with ICIs in HNSCC, only 20% to 30%
of patients with metastatic/recurrent cancer are disease-free at
2 years (1, 7) pointing to a long-term beneﬁt from anti–PD-1 monotherapy in HNSCC. Immunosuppressive cells, including Th2/M2
phenotype, anergic T cells, inhibitory costimulatory molecules (e.g.,
TIM 3, LAG3, TIGIT), and factors in the tumor microenvironment
(e.g., kynurenine, glycolysis) contribute to resistance to ICIs (8). This
has prompted investigation into combinatorial approaches to augment
the immune and clinical responses seen with PD-1 inhibitors.
The use of immunotherapy in the neoadjuvant setting is a particularly
appealing investigational approach, as it allows for the evaluation
of biologic specimens before and after treatment and can contribute to
the assessment of the treatment effect of novel combinations (9).
Preclinical models and clinical trials in solid tumors have indicated
the potential value of neoadjuvant immunotherapy in the preoperative setting (10–12). For example, a phase I/II neoadjuvant trial
(CheckMate 358) demonstrated safety in patients with HPV-positive
(HPVþ) and HPV HNSCC using preoperative nivolumab (13).
A clinical trial that enrolled patients with HNSCC treated with
neoadjuvant and adjuvant pembrolizumab showed a promising 1-year
relapse rate of 16.7% in high-risk patients (5). Additionally, this group
demonstrated a twofold increase in pathologic treatment response
(pTR) with the addition of a second cycle of ICIs in the neoadjuvant
setting (14).
Phosphodiesterase-5 (PDE-5) inhibitors, such as tadalaﬁl, increase
smooth muscle relaxation through the breakdown of cyclic guanosine
monophosphate (cGMP). Originally, this class of agents was used as a
treatment for pulmonary hypertension and was then applied in the
management of erectile dysfunction and benign prostatic hypertrophy (15). In a chance discovery, a patient being treated for multiple
myeloma who was placed on treatment for erectile dysfunction with
tadalaﬁl was noted to have remarkable effect on downregulation of the
immunosuppressive mechanisms (16). Further research to recapitulate this response in a mouse model and clinical trials found that PDE-5
inhibition alters antitumor immune responses by reprogramming
myeloid-derived suppressor cells (MDSCs) and enhancing T-cell
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Patients and Methods
Study population and design
We conducted a two-arm multi-institutional randomized trial
(NCT03238365). Eligibility included newly diagnosed and resectable
oral cavity, hypopharynx, larynx, or oropharynx HNSCC of any stage
[American Joint Committee on Cancer (AJCC) 8th edition]. Adequate
organ function was required as determined by hematologic and
biochemical parameters. Subjects could not have a history of an
autoimmune disorder, use of systemic steroids ≥ the equivalent of
10 mg of prednisone daily, human immunodeﬁciency virus, hepatitis
B/C, concurrent malignancies, angina, concurrent use of nitrates,
current use of PDE-5 inhibitors, or sickle cell anemia.
Upon enrollment, subjects underwent a biopsy of the primary site as
well as blood sample collection. CT or MRI was performed within
28 days of enrollment. Subjects were randomized 1:1 to receive
nivolumab (Bristol Myers Squibb) alone or nivolumab þ tadalaﬁl
(Eli Lilly and Company) with stratiﬁcation for HPV status. Subjects in
both cohorts received nivolumab 240 mg intravenously on days 1 and
15 followed by surgery on day 28. Subjects in the combination cohort
also received tadalaﬁl 10 mg orally once daily for 4 weeks initiated
concurrently with nivolumab. At the 4 weeks 3 days timepoint,
patients were reimaged and taken for deﬁnitive surgical resection of the
primary site and regional lymph nodes, as clinically indicated. Adjuvant treatment was decided by a multidisciplinary tumor board and
based on pathologic risk factors and pretreatment staging. At the time
of surgical resection, biopsies of the primary tumor, involved lymph
nodes, and blood were obtained and processed for correlative analysis.
Patients were followed for 3 months after surgery and evaluated for
surgical complications and adverse events (AEs). All AEs were collected prospectively using the Common Terminology Criteria for
Adverse Events (CTCAEs) version 4.03. Stopping rules were incorporated into the trial protocol for grade 3 to 5 AEs secondary to treatment
utilizing a Bayesian method of Thall and Simon (21). Our expected rate
of toxicity was 10%, and we set a limit of 15% toxicity as unacceptable.
This clinical trial was approved by Thomas Jefferson University and
Vanderbilt University Internal Review Board and all patients signed
informed consent. This trial was conducted in accordance with the
Declaration of Helsinki and the guidelines for Good Clinical Practice.
Assessment of pTR
Pathologic specimens were independently graded by two pathologists using scanned digital slides. For cases with a discrete mass lesion
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Neoadjuvant immune checkpoint inhibition is an attractive
approach for the treatment of squamous cell carcinoma of the head
and neck. In this setting, the addition of immune modulators to
immune checkpoint inhibitors has the potential to enhance antitumor effects. We evaluated the PD-1 inhibitor nivolumab alone or in
combination with the phosphodiesterase-5 inhibitor tadalaﬁl administered preoperatively in a randomized clinical trial. We demonstrated safety and antitumor effect in support of neoadjuvant use of
immune checkpoint inhibitors. While we did not show enhanced
clinical response with the addition of tadalaﬁl to nivolumab after
4 weeks, we demonstrated enhancement of B-cell– and natural killer
(NK)-cell–associated gene expression signatures in tumors that
respond to the combination. Our study provides a comprehensive
analysis of response to immune checkpoint inhibition in both human
papillomavirus–positive and human papillomavirus–negative squamous cell carcinoma of the head and neck and advocates for further
trials of phosphodiesterase-5 inhibition in this context.

responses. Speciﬁcally, PDE-5 inhibitors downmodulate arginase 1
and nitric oxide synthase-2 expression in tumor-associated myeloid
cells (17–19). Furthermore, in mice lacking critical elements of the
adaptive immune system (BALB/c-Rag-2/), PDE-5 inhibitors were
ineffective at altering the immune microenvironment. In aggregate,
these data support the hypothesis that PDE-5 inhibitors affect adaptive
immune responses by modulating innate immune cells. The observation that PDE-5 inhibition increased tumor inﬁltrating CD8þ T cells
associated with increased IL2 production in mouse models and clinical
trials further underscored the importance of T cells in PDE-5 inhibitor
effects (16, 20).
Here, we used a neoadjuvant (window of opportunity) paradigm
in the management of resectable HNSCC to test our hypothesis that
the addition of tadalaﬁl to nivolumab augments the antitumor effect
of nivolumab through modulation of the tumor microenvironment.
We report our correlative and clinical ﬁndings in patients with
HPVþ and HPV status.

Nivolumab and Tadalﬁl in Head and Neck SCC

Specimen processing and analysis
The primary endpoints were changes in IFNg, IL2, IL10, IL12 (p70),
and TNFb from the Luminex panel of inﬂammatory markers, representing a shift in immune-cell polarization (Th1/Th2; M1/M2). Secondary endpoints included safety, efﬁcacy, and collative analysis.
Details of specimen processing, RNA sequencing (RNA-seq), gene
set enrichment analysis (GSEA) analysis, ﬂow cytometric phenotyping, Luminex analysis, extracellular vesicle analysis, and IHC are all
provided in Supplementary Methods.
Statistical methods
Patients were randomized based on random permuted blocks
within strata deﬁned by location of tumor [oropharyngeal (HPVþ)
vs. nonoropharyngeal (HPV)]. The primary endpoints were changes
in IFNg, IL2, IL10, IL12 (p70), and TNFb from the Luminex panel of
inﬂammatory markers. A sample of 40 subjects with complete data
(20 per arm) was estimated to provide 80% power to detect a difference
in mean change between groups of 1.1 SDs at the a ¼ 0.01 level.
Descriptive statistics were used for demographic analysis. Adverse
events and pathologic response patterns were summarized by treatment arm. Fisher exact test was used to compare randomization
groups with respect to AE incidence and pattern of pathologic change.
Mixed effect regression analysis was used to model change in markers
from pretreatment to posttreatment. The markers were highly skewed,
so the outcome variables were log-transformed prior to modeling.

AACRJournals.org

From the model, we estimated the geometric mean of response, the
change of estimated geometric means of primary markers between
pretreatment and posttreatment by treatment group, and the multiplicative difference of the changes in the two groups. The signiﬁcance
level of all tests for the ﬁve primary outcomes was set a priori to the 0.01
level and to the 0.05 level for secondary outcomes. P values for
secondary outcomes were not adjusted for multiple comparisons.
Similar models were used to compare Rs to NRs with respect to
change in marker values by HPV status. Mixed effects regression was
performed with SAS 9.4 (SAS Institute Inc., Cary, NC).
For ﬂow cytometry analyses, all statistical analysis was performed using JMP software (SAS Institute). ANOVA followed by
Dunnett posttest analysis were used to determine relationships
between pretreatment and drug-treated response cohorts. Twoway Student t test was used to analyze differences between
pretreatment response cohorts.
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at the primary site, the entire mass was submitted for histologic
examination; for cases without a discrete mass lesion, the entire
specimen was examined histologically. All lymph nodes with metastatic disease (either viable or nonviable tumor cells) or evidence of
treatment response were also included in the analysis. pTR was scored
as follows: pTR % ¼ areas of treatment response/total tumor surface
area (5). The histologic criteria constituting pTR included areas of
macrophage reaction, multinucleated giant cells and granulomas (with
or without associated keratin debris), ﬁbrosis, and chronic inﬂammation adjacent to residual tumor nests. In cases of complete response,
distortion of the normal architecture of the organ at the primary site or
the lymph node architecture was included as an indicator of treatment
response. pTR on the posttreatment specimen was used as our
classiﬁcation of whether a patient was a complete responder, responder, minimal responder, or nonresponder. A priori, tumors with pTR of
≥20% were deﬁned as responders (Rs), whereas those with pTR <20%
were deﬁned as “minimal” responders. Specimens with 0% were
deﬁned as pathologic “nonresponders” (NRs) and specimens with
100% pTR were “complete responders” (CRs). For purposes of analysis, we prospectively designated Rs as those with ≥20% pTR and
NRs as less than 20% pTR.
Clinical staging was determined at time of enrollment using the
AJCC 8th edition clinical exam and CT and F-ﬂuorodeoxyglucosePET/CT scans. Correlation of imaging to pathologic response has
previously been published (22). Two head and neck pathologists
determined pathologic staging after resection of primary tumor and
lymph nodes. We elected to look at changes in staging from
pretreatment clinical stage to posttreatment pathologic stage as
this comparison resolves the anticipated background noise that
many result from differing states of ﬂuctuation and inﬂammation,
especially if ﬁne-needle biopsy was involved in the diagnostic workup making radiographic staging less reliable as compared with
pathologic staging. In addition, pathologic changes represent the
clinical paradigm more accurately in patients treated with upfront
surgery where clinical staging is superseded by pathologic staging.

Results
Between August 2017 and July 2019, 50 patients provided consent
and were randomized. Of these, 45 enrolled and completed treatment
at two institutions. Demographic and tumor characteristics were
similar between those receiving nivolumab alone (n ¼ 20) versus
nivolumab þ tadalaﬁl (n ¼ 25; Table 1). Trial schematic, example of
response, and waterfall plot of pathologic response are presented
in Fig. 1.
Nivolumab alone and the combination with tadalaﬁl were welltolerated with no grade 3 to 5 treatment-related AEs or grade 3 to 5
immune-related AEs (IRAEs; Table 2). There were no treatmentrelated delays in surgical intervention. There were no appreciable
wound-healing delays after surgery. Unrelated to investigational
treatment, one patient in the nivolumab-alone group was newly
diagnosed with asymptomatic coronary artery disease on the preoperative risk stratiﬁcation workup, resulting in cardiac revascularization that delayed the surgery intervention by 6 weeks. This
patient was found to have no evidence of tumor in his ﬁnal
specimen. Eleven patients in the combined nivolumab þ tadalaﬁl
arm developed grade 1 or 2 headaches as compared with three in the
nivolumab-alone group (P ¼ 0.06).
In the analysis of our primary outcomes, we did not ﬁnd a difference
in pretreatment peripheral cytokines in nivolumab alone versus
nivolumab þ tadalaﬁl or in Rs versus NRs. When the analysis was
subdivided to look at patients with HPV and HPVþ status independently, those with HPV status had three cytokines that demonstrated
a signiﬁcant change after treatment in Rs although they are
not connected to a discrete immune pathway (granulocyte colonystimulating factor, IL9, IL1A; Supplementary Fig. S1; Table 1).
Neoadjuvant nivolumab yields greater than 50% of patients
with pathologic response regardless of tadalaﬁl or HPV status
Of 45 patients evaluable for pTR, 26 (58%) had an overall
pTR ≥ 20% at the primary and lymph node sites: three patients
(7%) demonstrated complete response (CR) with a pTR of 100%,
and 23 (51%) were Rs with a pTR 20% to 99%. Nine (20%) patients
were minimal Rs with a pTR of 1% to 19%, and 10 (22%) had
pTR of 0% and were thus categorized as NRs. When comparing
Rs (CRs þ Rs) with poor or NRs (MRs þ NRs), there was a signiﬁcant
association between the presence of IRAEs and pTR. During the
study period, 10 (22%) patients had grade 1 or 2 IRAEs: six
with dermatitis, four with thyroiditis, and one with both (Table 2).
Almost all of the patients who presented with IRAEs (90%) were
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Table 1. Patient demographics.
Nivolumab alone
(n ¼ 20)

Nivolumab þ tadalaﬁl
(n ¼ 25)

63 (11)
41:4

61 (12)
19:1

65 (10)
22:3

6 (13)
15 (33)
24 (53)

2 (10)
7 (35)
11 (55)

4 (16)
8 (32)
13 (52)

22 (49)
23 (51)

10 (50)
10 (50)

12 (48)
13 (52)

11 (24)
19 (42)
4 (9)
11 (24)

5 (25)
7 (40)
2 (10)
5 (25)

6 (24)
11 (44)
2 (8)
6 (24)

11 (24)
25 (56)
4 (9)
3 (7)
1 (2)
1 (2)

5 (25)
12 (60)
0 (0)
1 (5)
1 (5)
1 (5)

6 (24)
13 (52)
4 (16)
2 (8)
0 (0)
0 (0)

16 (36)
7 (15)
22 (49)

6 (30)
2 (10)
12 (60)

10 (40)
5 (20)
10 (40)

31 (69)
14 (31)

15 (75)
5 (25)

16 (64)
9 (36)

Note: Former smoker: quit more than 6 months earlier with greater than 10 pack-years. Moderate/heavy alcohol: more than two drinks/night on average.

pathologic Rs at the primary site and lymph nodes by pTR criteria
(P ¼ 0.0132).
The addition of tadalaﬁl to nivolumab did not result in a greater
pTR overall: 32.7% nivolumab alone versus 28.8% nivolumab þ
tadalaﬁl (P ¼ 0.676; Fig. 1C). There was no difference in treatment
response by HPV status with mean pTR of 30% in the HPV group and
31% in the HPVþ group (P ¼ 0.845). Half of the subjects with involved
lymph nodes had discordance of treatment response at the primary site
versus lymph nodes (22). Radiographic volumetric response correlated
with pTR as previously published, demonstrating signiﬁcant correlation at the primary tumor site (P < 0.001) as well as at metastatic lymph
nodes (P < 0.05; ref. 22). Patients with HPVþ status had signiﬁcantly
better disease-free survival (DFS), disease-speciﬁc survival (DSS), and
overall survival [overall survival (OS); P ¼ 0.018 for DFS, P ¼ 0.031,
and P ¼ 0.017 for OS; Supplementary Fig. S6A] compared with
patients with HPV status. Among patients with HPV status, overall
survival is trending toward improvement in those who had evidence of
pathologic response (Supplementary Fig. S6D). However, we did not
observe any signiﬁcant difference in DFS, DSS, and OS by treatment
response status (P ¼ 0.281 for OS; Supplementary Fig. S6D).
For all patients completing the trial, the T-stage was downstaged in
nine patients from the pretreatment clinical stage to the ﬁnal pathologic stage and upstaged in one patient. Most remarkable were three
patients downstaged from T2 to T0 (Table 3). Nodal status was
downstaged in three patients. Two patients had signiﬁcant progression
of disease after initiating study treatment. Both patients were HPV
oral cavity primaries and had progression only at the primary site as
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evident by repeat CT scans. These patients received only one dose of
immunotherapy before being taken off the study due to progression.
The ﬁrst patient who received nivolumab alone had hyperprogression
(3.1  1.5 cm increasing to 5.5  2.5 cm on CT scan, representing a
>twofold tumor growth rate before treatment to after treatment) at
2 weeks (23). This patient was taken at week 2 to the operating room for
resection. There was no pTR at the primary site, although there was
95% pTR in one lymph node without any evidence of disease or pTR in
other nodes. The second patient who received nivolumab þ tadalaﬁl
was taken off the trial after the ﬁrst dose of nivolumab due to clinical
evidence of progression and placed on induction cisplatin þ docetaxel
followed by surgical resection. Final pathology revealed 95% pTR
secondary to induction chemotherapy. Three additional patients were
upstaged from clinical to pathologic staging based on nodal status
(from N0 to N1) with deposits of carcinoma ranging from 1 mm to
12 mm within a lymph node consistent with occult disease and not
secondary to progression. Each of the patients that had ﬁndings of
occult metastasis on pathologic review, upstaging from N0 to N1, were
in the nivolumab þ tadalaﬁl cohort. We do not have any biologic
explanation for this being found only in the cohort with nivolumab þ
tadalaﬁl but do not ﬁnd it to be clinically signiﬁcant, as adjuvant
treatment recommendations were not changed.
T cells are predictive of response in HPV but not HPVþ tumors,
whereas tumor proliferation index is predictive in all tumors
Comparison of biomarker changes in Rs and NRs was performed in
pretreatment samples in both arms combined using pTR deﬁnitions

CLINICAL CANCER RESEARCH
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Mean age (SD)
Male:female
Primary site, n (%)
Larynx/hypopharynx
Oral cavity/nasal cavity
Oropharynx
HPV, n (%)
Positive
Negative
cT stage (8th edition), n (%)
T1
T2
T3
T4
cN stage (8th edition), n (%)
N0
N1
N2 (HPV oropharynx)
N2a
N2b
N3
Smoking status, n (%)
Never
Current smoker
Former smoker
Alcohol status, n (%)
None/light
Moderate/heavy

All data
(n ¼ 45)

Nivolumab and Tadalﬁl in Head and Neck SCC

provided (see Supplementary Data for details of biomarker analysis).
Analysis of combined pretreatment tumor RNA-seq showed that Tcell signature and PD-L1 expression agnostic of HPV status were not
signiﬁcantly correlated with response (Fig. 2A and B). On subanalysis
of the T-cell signatures between HPVþ and HPV tumors, we found
overall T cells, CD4þ, CD8þ, and regulatory T cells (Tregs) were
predictive of response in the HPV cohort alone (Fig. 2A). IHC
conﬁrmed this ﬁnding: HPV Rs had signiﬁcantly more CD8, FoxP3,

AACRJournals.org
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Figure 1.
Trial schema and overall response.
A, Trial schema. B, Example of
radiographic and pathologic representation of treatment response. A
6-cm pretreatment lymph node
decreased to 3.4 cm posttreatment and on ﬁnal pathology had
95% pTR with only 5% viable tumor
in the lymph node (yellow arrow).
C, Waterfall plot of overall pTR by
treatment group and HPV status at
time of surgery. Threshold of ≥20%
was considered a “responder” in
the correlative analysis. Analysis of
tumor tissue used pTR at the primary site only. Analysis of PBMCs
used overall pTR including primary
and lymph nodes. OC, oral cavity;
HP, hypopharynx; NC, nasal cavity.

and CD163 cells while the NR group presented as an immune cell
desert, void of all immunoreactivity for immune cells. HPVþ tumors
had a higher abundance of immune cells compared with HPV tumors
but did not demonstrate a different proﬁle in the pretreatment samples
(Fig. 2A). Pretreatment PD-L1 RNA signature and IHC was not
predictive of pathologic response (Fig. 2B). Interestingly, tumor
proliferation rate signatures (24) were signiﬁcantly associated with
NRs regardless of HPV status (P ¼ 0.007; Fig. 2C).
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Table 2. Adverse events.
Nivolumab alone
(n ¼ 20)

Nivolumab þ tadalaﬁl
(n ¼ 25)

P value

(0)
6 (13)
0 (0)
4 (9)
0 (0)

0 (0)
4 (20)
0 (0)
3 (15)
0 (0)

0 (0)
2 (8)
0 (0)
1 (4)
0 (0)

—
0.240
—
0.198
—

14 (31)
15 (33)
9 (20)
1 (2)
6 (13)
3 (7)
7 (16)
9 (20)

3 (15)
5 (25)
4 (20)
1 (5)
3 (15)
2 (10)
2 (10)
4 (20)

11 (44)
10 (40)
5 (20)
0 (0)
3 (12)
1 (4)
5 (20)
5 (20)

0.054
0.352
1.000
0.444
0.768
0.192
0.437
1.000

Note: All immune-related adverse events and adverse events were grade 1 or 2.

ICI Rs reveal higher peripheral B-cell count and CD8þ:CD4þ
ratio, and lower peripheral PDL1 and CD163 pretreatment
The peripheral blood mononuclear cell (PBMC) analysis
revealed that Rs have a greater number of B cells (P ¼ 0.007)
(Fig. 3). The R group had a lower absolute peripheral T-cell count
(P ¼ 0.001), but the ratio of CD8þ:CD4þ T cells was far greater in
the responder group as compared with NRs (P ¼ 0.03), pointing to
a greater effector population. Interestingly, nivolumab þ tadalaﬁl
showed a greater CD8þ:CD4þ ratio after treatment regardless of
response (Fig. 3). From a biomarker standpoint, pretreatment
peripheral PD-L1 and CD163 were both signiﬁcantly downregulated in the R group as compared with the NR group, suggesting a
less suppressive peripheral environment at the start of treatment
(Fig. 3).
Tadalaﬁl ampliﬁes B and NK cells present in Rs, posttreatment
RNA-seq revealed that HPVþ tumors had an increased gene
expression associated with B- and T-cell immune signatures with
nivolumab plus tadalaﬁl when compared with nivolumab alone,
regardless of response (Fig. 4A). In contrast, HPV tumors had
lower expression of all immune signatures (B, T, NK etc.) after
receiving tadalaﬁl when compared with nivolumab alone, indicating a clear differential response in HPVþ versus HPV tumors at

the transcriptomic level when analyzed in aggregate and regardless
of response. Parallel deconvolution of cell types by Kassandra
algorithm found conﬁrmatory results in the B-cell population (25).
Dynamic changes caused by tadalaﬁl in both a signature change
and percent cell change included a signiﬁcant increase in B-cell
population and upward trends in the T-cell population when
analyzed agnostic to HPV status (Fig. 4B). Signatures associated
with cancer-associated ﬁbroblasts did not show any change
between the two cohorts (Fig. 4B). Although there was no correlation to response, HPVþ tumors demonstrated a higher level of
RNA expression of 292 immune genes as compared with the HPV
cohort (Supplementary Fig. S2).
To further look at differences in response, we performed GSEA of
bulk RNA sequences from post- versus pretreatment samples. Unbiased query with gene set collections from the Molecular Signatures
Database (MSigDB) 7.2 (26, 27) revealed the most signiﬁcant enrichments in the C2 canonical pathway, C5 bioprocesses, and C8 cell-type
signature collections were B-cell– and NK-cell–related gene sets. In the
canonical pathway collection, B-cell–related gene sets included those
for B-cell receptor regulation, Fc gamma receptor activation, and
complement triggering (Fig. 5A; Supplementary Fig. S3A and S3B).
For instance, CD22-mediated B-cell receptor regulation elevated to
normalized enrichment scores (NES) of 3.97 (FDR q value 0.000) and

Table 3. Change of staging after 4 weeks of treatment.
Pretreatment clinical stage
change to pathologic stage

All
(N ¼ 45)

Nivolumab alone
(n ¼ 20)

Nivolumab þ tadalaﬁl
(n ¼ 25)

T1!T0
T2!T0
T2!T1
T3!T4a
No change in T stage
N1!N0
N0!N1
No change in N stage

1 (2)
3 (7)
4 (9)
1 (2)
36 (80)
3 (7)
4 (9)
38 (84)

1 (5)
1 (5)
1 (5)
0 (0)
17 (85)
0 (0)
0 (0)
20 (100)

0 (0)
2 (8)
3 (12)
1 (4)
19 (76)
3 (12)
4 (16)
18 (72)
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P value
0.792
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Immune-related adverse events
(Grade 1 or 2), n (%)
Pneumonitis
Dermatitis
Hepatitis
Thyroiditis
Gastroenteritis
Adverse events (Grade 1 or 2), n (%)
Nonimmune related
Headache
Fatigue
Myalgia
Presyncope
Arthralgia/fever/chills
Wound complications
Nausea/vomiting
Diarrhea

All
(N ¼ 45)
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Figure 2.
HPV Rs have increased pretreatment T-cell abundance. A, Pretreatment biopsy CD8þ T-cell RNA signature did not demonstrate signiﬁcance between Rs and NRs.
Subgroup analysis with respect to HPV status reveals the HPV cohort having a signiﬁcant difference in overall T cells, Tregs, CD8, and CD4 that is not identiﬁed in the
HPVþ cohort. Pretreatment CD8, FoxP3, and CD163 IHC conﬁrm a signiﬁcant difference for HPVbut not positive tumors pointing to an immune desert as a signiﬁcant
correlate of nonresponse. B, Quantitation by RNA-seq of PD-L1 and semiquantiﬁcation by PD-L1 IHC staining demonstrating no predictive signiﬁcance for response
(left graph, y-axis shows log2 expression). In pre- to posttreatment samples PD-L1 staining remained stable in the NRs and trended upward in the Rs (right graph).
C, High tumor proliferation rate signatures in the pretreatment samples are associated with nonresponse. The tumor proliferation signature consists of cell cycle– and
tumor progression–associated genes.

3.4 (FDR q value 0.000) in HPVþ and HPV nivolumab þ tadalaﬁl Rs,
respectively, posttreatment (Fig. 5A, top left). In contrast, treatment
with nivolumab alone did not result in the posttreatment enrichment
of these gene sets (Supplementary Fig. S3B). Unbiased query with
the bioprocesses component of the C5 collection conﬁrmed posttreatment B-cell pathway enrichments in HPVþ and HPV nivolumab þ
tadalaﬁl Rs (not shown).
Next, an unbiased GSEA query was performed with the celltype signature collection C8, which sources single-cell RNA-seq
studies. GSEA revealed that B cells and NK cells were among those
most enriched in Rs with the addition of tadalaﬁl. The pattern of B-cell
enrichment seen in C8 was consistent with the enrichments in B-cell
canonical pathways observed in C2 and C5. NK-cell gene sets
described by Aizarani and colleagues (2019) accounted for four of
the top ﬁve hits in HPVþ nivolumab þ tadalaﬁl Rs posttreatment
(Supplementary Table S1; ref. 28). The highest NES was 3.81; FDR
q value 0.000 for HPVþ and NES 3.00; FDR q value 0.000 for HPV
(Fig. 5A, bottom, middle). In contrast, nivolumab-alone Rs showed
no enrichment (HPVþ NES 0.97, FDR q value 0.606; HPV NES 1.28,
FDR q value 0.162).
Normalized transcript counts for subsets of coordinately expressed
B-cell or NK-cell genes were illustrated in scatter plots and again in line
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plots to detail the full spectrum of response (% pTR) from NR to
complete response. Upregulation in the posttreatment group was
observed in the presence of nivolumab þ tadalaﬁl, but not in the
nivolumab-alone group, beginning at 20% pTR for B-cell genes
(Fig. 5B, top; Supplementary Fig. S4A and S4B) and NK-cell genes
(Fig. 5B, bottom; Supplementary Fig. S5A and S5B).
To further characterize the association between the nivolumab þ
tadalaﬁl combination and NK cells, we performed supervised GSEA
and qualitative Venn diagram analysis of leading edges (Fig. 5C).
To identify quantitative changes in the nivolumab þ tadalaﬁl versus
nivolumab-alone leading edges, a side-by-side comparison of rankin-gene-list was performed for each gene (Supplementary Table S2).
As detailed in the Supplemental Results, an extensive set of genes
was found to be (i) enriched only with nivolumab þ tadalaﬁl and
(ii) upregulated compared to nivolumab alone, with gene rankings
that were vastly different between the groups (e.g., CD69, CXCR4,
GMZK, DUSP2).
Overall, the addition of tadalaﬁl to patients with HPVþ status
resulted in the greatest increase in B- and T-cell gene signatures
regardless of response. When stratiﬁed by response, GSEA identiﬁed
consistent upregulation of B- and NK-cell gene expression in all Rs
with the addition of tadalaﬁl.

Clin Cancer Res; 28(5) March 1, 2022

921

Luginbuhl et al.

Increased circulating exosomes and increased immune
checkpoint receptors observed in exosomes isolated from
NRs
Flow cytometric analysis of exosomes in pre- and posttreatment
plasma (n ¼ 41) and supernatants (n ¼ 23) from short-term ex vivo
tumor cell cultures showed a signiﬁcant increase in circulating
exosomes in the NRs as compared with Rs. Expression of immune
checkpoint receptors on exosomes present in posttreatment tumor
culture supernatant point to an increase in checkpoints that inhibit an
immune response (PD-L1, LAG3, and TIM3) in the tumor supernatants of subjects who did not have a pathologic response (Fig. 6).

Figure 3.
Flow cytometric analysis of peripheral blood cell subsets shows that Rs have
different pretreatment peripheral compartments that support cytotoxic T
cells. Scatter graphs depict representative subjects with numbers indicating
the percentage of cells within a given gate. Graphs show NRs and Rs baseline
pretreatment values compared with posttreatment nivolumab versus nivolumab þ tadalaﬁl. Rs demonstrated a greater CD8:CD4 ratio in the periphery
with the tadalaﬁl cohort signiﬁcantly augmenting this ratio after treatment
regardless of response. In pretreatment samples, B lymphocytes are
increased. Peripheral PD-L1 levels and CD163 macrophages are signiﬁcantly
decreased in Rs compared with the NRs, suggesting the peripheral compartment plays role in treatment response. Statistical signiﬁcance was
assessed using ANOVA ( P < 0.05,   P < 0.001,    P < 0.0005). Nivo,
nivolumab; Tad, tadalaﬁl.
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Neoadjuvant preoperative treatment with nivolumab with or without tadalaﬁl was safe and demonstrated a wide variety of pTRs ranging
from no response to CR. There was evidence that tadalaﬁl triggered
an adaptive immune response, however, the 4-week window-ofopportunity treatment with tadalaﬁl did not produce a statistically
signiﬁcant increase in pTR. A drug exposure of 4 weeks may not have
been long enough to result in a therapeutic effect of priming with
tadalaﬁl to improve the immune checkpoint response. However,
despite the small sample size, ﬁndings within the pretreatment samples
point to predictive modeling of response in an HPV-dependent
manner.
This trial contributes to emerging neoadjuvant therapy data
supporting safe use of immune checkpoint inhibitors in previously
untreated early-stage HNSCC, including HPVþ tumors. Other trials
have also demonstrated the safety of nivolumab in the neoadjuvant
setting (4, 5). Our cohort of 45 patients did not experience any grade
3 or greater IRAE or severe AEs nor were any surgical cases delayed
due to AEs or postoperative complications related to immunotherapy or tadalaﬁl treatment observed. Our rate of IRAEs is consistent
with reported data from ICI monotherapy trials in recurrent
or metastatic HNSCC, however, our period of observation is
short (1, 3, 7). Of clinical interest was the association we found
between the presence of grade 1 or 2 IRAEs (dermatitis/thyroiditis)
and pTR. This is an intriguing observation in the neoadjuvant
setting of short drug exposure. Previous studies in various advanced
solid tumors have shown an association between the emergence of
IRAEs and ICI efﬁcacy (29–32).
Another point of interest is our analysis based on HPV status.
Overall, 63% of the HPVþ tumors had a pTR greater than 20%
with nivolumab þ/ tadalaﬁl. However, HPV status was not
a predictor of pTR response to PD-1 blockade, and our interrogation
did not reveal an immune-related pretreatment proﬁle that could
predict response in patients with HPVþ tumors as gauged by tumor
proliferation. HPV-associated tumors develop within the tonsillar
lymphoid tissue, an immune-rich host environment. Therefore,
escape mechanisms may develop early in tumor evolution in HPVþ
HNSCC (33). Aggarwal and colleagues primed an active immune
response in patients with HPVþ tumors by using DNA immunotherapy targeting HPV 16/18 E6/E7 with IL12 encoding plasmids and
showed a durable antigen-speciﬁc peripheral tumor immune response,
but with a concomitant increase in PD-1/PD-L1 activation (34). In our
cohort of patients, tadalaﬁl likewise increased the immune-associated
gene expression proﬁle of an active adaptive immune response (Fig. 5;
Supplementary Fig. S3).
Our data set did not demonstrate that PD-L1 IHC and HPV status
were predictive of response to immunotherapy. In the pooled clinical
trial data analysis by Wang and colleagues, patients with higher PD-L1
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Figure 4.
HPVþ tumors demonstrate the greatest overall immune-related transcriptomic change with the addition of tadalaﬁl. A, Heatmap showing expression of a set of 292
immune signature genes comparing pre- and posttreatment separated out by HPV status and treatment cohort regardless of response. Individual genes
(demarcated by rows) are subdivided based on immune cell association (vertical legend). Each column represents a cohort prior to treatment or following
treatment. B, Gene signatures demonstrate dynamic changes caused by tadalaﬁl in the B-cell population, with upward trend in the T-cell population and no
effect on CAFs.  P < 0.05,   P < 0.01. Nivo, nivolumab; Tad, tadalaﬁl.

expression who were treated with PD1– or PD-L1–directed immune
checkpoint inhibitors had higher response rates compared with those
with low PD-L1 expression (1, 3, 7, 35, 36). Similarly, in the previously
untreated patient population of the KEYNOTE-048 trial, higher
PD-L1 expression correlated with higher response rates to pembrolizumab monotherapy (7). Nevertheless, PD-L1 expression was
not useful in predicting survival beneﬁt from nivolumab in the
phase III CheckMate 141 trial (1). In a neoadjuvant trial, PD-L1
combined positive score ≥ 1 was not independently associated with
1-year DFS but was highly associated with pTR (P ¼ 0.0007),
demonstrating the difﬁculty with PD-L1 acting as the only prognosticator of outcomes (37). It is unclear whether HPV status
results in a differential response to ICIs in HNSCC. In the analysis
by Wang and colleagues, the authors proposed that the HPVþ
inﬂamed immune microenvironment would result in an improved
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immunotherapy response (36). However, in our dataset, this was
not the case. To supplement this question, we looked at IFNg
signatures in the bulk RNA-seq and did not identify any predictive
ﬁndings (Supplementary Fig. S7).
We were, however, able to identify a pretreatment proﬁle that
predicted pTR in the HPV cohort. Quantitative IHC evaluation
revealed an immune cell desert in HPV NRs, with a signiﬁcantly
higher number of CD8þ, FoxP3þ, and CD163þ cells in the stroma,
tumor, and stromal/tumor interface in HPV Rs. In our RNA-seq
analysis, HPV tumors demonstrated a signiﬁcant correlation between
pretreatment expression of T-cell–speciﬁc genes (Treg, CD8þ, CD4þ)
and response. This same pretreatment proﬁle was not found in the
HPVþ cohort. In a comprehensive proteo-genomic study of 108 HPV
tumors, investigators found that widespread deletion of immune
modulatory genes (through somatic mutation or genomic loss)
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accounted for the low immune inﬁltration in immune cold-tumors.
Conversely, tumors with some immune inﬁltrate also have upregulation of checkpoints (38). It is important to note that, in our cohort,
neither the PD-L1 IHC nor the absolute level of T-cell expression was
predictive of response, regardless of HPV status. Outside the scope of
this research, but certainly informative, would be a multiplex platform
adding important geographic cell–cell dimension to this analysis.
The observation that exosome levels were greater in the periphery of
NRs than in the Rs has a number of potential implications. The role of
circulating vesicles has yet to be established in tumor patients, and one
signiﬁcant risk is the potential to inhibit antitumor immunity in the
tumor microenvironment thus reducing the efﬁcacy of an ICI. This is
exempliﬁed in Schroeder and colleagues’ work, noting the concentration of circulating exosomes was increased in patients with HNSCC as
compared with healthy donors resulting in an inhibitory effect on the
function of B cells (39). Our data showing elevated PD-L1, TIM3, and
LAG 3 in NRs, in addition to others, demonstrate that exosomes can
have an inhibitory function (40). The complexity of immunotherapy
success or failure demands a holistic understanding, including periphery and local tumor microenvironment, to ultimately predict response
to ICIs (28).
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The addition of tadalaﬁl to nivolumab resulted in a signiﬁcant
immune-related transcriptomic change that points to B-cell–
associated genes as a prime target. Additionally, we demonstrated
that tadalaﬁl increased the peripheral complement of effector T cells,
as demonstrated by a signiﬁcant augmentation of the CD8:CD4 ratio.
Further, GSEA suggests a role for the nivolumab and tadalaﬁl combination in NK-cell reprogramming. After treatment, a 92-gene
leading edge of an enriched NK-cell gene set was shown to contain
activation-related markers in the nivolumab þ tadalaﬁl group, relative
to the nivolumab-alone group. Conceivably, these genes represent an
expression signature for reactivation of tumor-induced NK-cell
exhaustion. At present, however, it is important to recognize that this
is a GSEA-based hypothesis. Given the effects of the nivolumab and
tadalaﬁl combination treatment on both B- and NK-cell gene sets, it
may also be hypothesized that tumor cell killing is occurring via
antibody-dependent cell-mediated cytotoxicity. With recent data
demonstrating a NKTR-255, a congregated IL15 molecule, having an
antitumor effect through activation of NK cells supports the further
investigation into NK strategies. Tadalaﬁl, with its strong history of
safety in a longer-term strategy, may have therapeutic beneﬁt (41). A
pilot trial utilizing tadalaﬁl in patients with melanoma demonstrated
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Figure 5.
Unbiased GSEA of bulk RNA sequences, indicating enrichment of B- and NK-cell gene sets in Rs to nivolumab and tadalaﬁl. A, Enrichment plots and heat maps. Top,
left: Result from a canonical pathway collection (C2 cp) query showing enrichment of CD22-mediated B-cell antigen receptor regulation in HPV and HPVþ Rs,
posttreatment. Top, right: Cell-type signature (C8) query revealing enrichment of B cells. Heatmaps show the 12-most upregulated genes, posttreatment. Bottom,
left: Cell-type signature collection (C8) query illustrating enrichment of an NK-cell gene set in HPV and HPVþ Rs. Bottom, right: Enrichment of a second NK-cell gene
set, with portions of heatmaps. B, Scatter plots of normalized transcript counts from bulk RNA sequence data. Top: Expression of B-cell genes, selected from heat
maps in panel A. Enrichment, posttreatment, manifested in the 20% to 100% pTR group that received nivolumab þ tadalaﬁl (left; one-way ANOVA; P < 0.0001), but
not nivolumab-alone (right). Bottom: Similarly, a subset of ﬁve NK-cell genes were found to be enriched by tadalaﬁl in the 20% to 100% pTR group, posttreatment
(one-way ANOVA; P ¼ 0.0003). C, Venn diagram of the GSEA leading edges and table of the 66 genes of an NK-cell signature unique to the tadalaﬁl group. NS, not
signiﬁcant.
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stability of disease in three of 12 patients (25% of patients and in this
group), and there was a signiﬁcantly higher number of CD8þ tumorinﬁltrating lymphocytes (TILs) in the center of the metastases before
treatment as compared with patients who progressed. After treatment,
there was an increase in expression of g-chain (marker of T-cell
activation) in CD8 and CD4 TILs and CD8þ T cells in the peripheral
blood as compared with baseline (42). In HNSCC trials using PDE-5
inhibitors, correlative ﬁndings demonstrated reduction in MDSCs,
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Figure 6.
Flow cytometric analysis of exosomes in preand posttreatment plasma and supernatants
from short-term ex vivo tumor cell cultures
identiﬁed increase exosomes in NRs. A, Gating
strategies for single events (left) and exosomes
(right). B, The frequency of circulating
exosomes in pretreatment plasma (n ¼ 41; left)
and overnight biopsy cultures (n ¼ 23; right) as
they relate to clinical response. Statistical signiﬁcance was assessed using ANOVA ( P ¼
0.03). C, Bar charts show expression of immune
checkpoint receptors on exosomes present in
posttreatment tumor culture supernatant as
they relate to clinical response (n ¼ 23). Statistical
signiﬁcance was assessed using Student t test
( P < 0.05). Exo, exomes; MFI, mean ﬂuorescence intensity; FSC-A, Forward scatter area;
FSC-H, forward scatter height; DiO, 3,30 dioctadecyloxacarbocyanine; TCS, tumor
culture supernatant.

Tregs, and augmented effector response with CD8þ TILs (17–19). A
Veterans Affairs study with 221,538 participants demonstrated
patients taking PDE-5 inhibitors for erectile dysfunction had a lower
hazard of colorectal cancer as compared with those not on PDE-5
inhibitors (43). Additional trials in hepatocellular carcinoma and other
abdominal malignancies are currently enrolling subjects.
Our randomized clinical trial adds to the body of literature that
tadalaﬁl is active at augmenting the immune microenvironment and
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raises the novel possibility that tadalaﬁl can reprogram NK cells. The
short duration of this trial is a limitation; follow-up studies are needed
to explore the extended use of tadalaﬁl in the setting of PD-1
checkpoint inhibition in individuals who respond to treatment. Additionally, our results provide further support for the exploration of the
PD-1 blockade in the previously untreated HNSCC. Finally, the data
presented here also points to the importance of understanding treatment response and predictors of response that differentiate tumors
according to their HPV status.
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